

PreveCeutical Medical Inc.

15:15 18 Apr 2019

PreveCeutical partnership leads to two new patent filings targeting non-addictive alternatives to opioid painkillers

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) unveiled promising news Wednesday that it has applied for two patents in Australia alongside research collaboration partner UniQuest (UQ) and The University of Queensland in developing non-addictive alternatives to opioid painkillers, through the use of cyclic peptides.

The Vancouver-based company's efforts in peptide research for pain relief are ramping up, and the two new Australian patent applications are based on the company's research collaboration UQ and UniQuest, with new intellectual property being discovered from its non-addictive analgesics program at UQ.

"The research program aims to develop a non-addictive alternative to opioid painkillers by developing cyclic peptides. Opioid-based pain treatments such as morphine, codeine and fentanyl activate the mu opioid receptor, which can be highly addictive," said PreveCeutical President and Chief Science Officer Dr Mak Jawadekar in a statement. "This research provides a potential mechanism for pain treatment without activating that receptor. An additional potential advantage of the cyclic peptides is their enhanced metabolic stability and more importantly oral bioavailability, meaning that they could be taken orally rather than intravenously."

Peptides are currently being used to target an array of disease indications including metabolic disorders, pain, cancers, cardiovascular and infectious diseases.

READ: PreveCeutical Medical applies to acquire human tissue for next phase of Sol-gel technology testing

It's clear that the opioid epidemic has led to significant numbers of opioid-related deaths and addictions, taxing public health care systems and affecting social and economic welfare.

PreveCeutical currently has five research and development programs underway, including gene therapy for diabetes and obesity, non-addictive analgesic peptides to replace fentanyl and the like, and soluble drug delivery program, among others.


The two-year research program into the peptides and its potential application as a treatment for pain, is being led by UQ School of Pharmacy researchers, Associate Professor Peter Cabot and Dr Harendra (Harry) Parekh. UQ specializes in commercialising intellectual property of The University of Queensland.

"The patent applications represent an important milestone in our relationship with PreveCeutical and follow the entry into three other research agreements with PreveCeutical in recent years, including an agreement to stabilise peptides isolated from scorpion venom for use in immune-boosting applications; an agreement for the development of a new formulation to deliver cannabinoids directly to the central nervous system via the nasal cavity; and an agreement for a gene therapy to treat diabetes and obesity," said UniQuest CEO Dr Dean Moss.

Price: 0.06

Market Cap: \$23.79 m

1 Year Share Price Graph



Share Information

Code: PREV

Listing: CSE

52 week High Low
0.06 0.01

Sector: Medical technology & services

Website: preveceutical.com

Company Synopsis:

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

action@proactiveinvestors.com

Shares of PreveCeutical were at C\$0.07 in Toronto and at US\$0.05 in New York on Thursday.

Contact Katie Lewis at katie@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).